Objectives: To determine the prevalence of prostate cancer and to assess potential associations between race and prostate adenocarcinoma according to age in patients followed in an outpatient service of general urology in an university hospital.
Materials And Methods: Retrospective study of men aged from 40 to 79 years, followed during the period from 1999 to 2001. Patients were classified according to race in White, Mulatto and Black. Those with abnormal digital rectal examination and/or serum level of prostate specific antigen (PSA) > 4.0 ng/ml, underwent a transrectal prostate biopsy.
Results: 580 patients with mean age of 60.7 +/- 10.0 years were studied, with 116 Whites (20.0%), 276 Mulattos (47.6%) and 188 Blacks (32.4%). There was no significant difference regarding the mean age (p = 0.62), serum level of PSA (p = 0.65) and prevalence of prostate adenocarcinoma between Whites, Mulattos and Blacks (p = 0.36). While studying the association between race classified in 2 groups (Whites versus Mulattos and Blacks) and prostate adenocarcinoma according to age, no association was found when the total group was assessed, neither among those with age above 60 years old. In the group between 40 and 60 years, even though without statistical significance, the estimate of prevalence ratio was 2.2 (CI 95%: 0.52 to 9.0; p = 0.38).
Conclusion: Prostate adenocarcinoma was found in 16.6% of the patients aged between 40 and 79 years. We did not find a racial influence in our population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s1677-55382003000400004 | DOI Listing |
Introduction: Prostate cancer is incidentally diagnosed in 6%-11% of benign prostatic hyperplasia surgeries.
Case Presentation: A 79-year-old man was diagnosed with benign prostatic hyperplasia. The prostate volume was 54.
Pathologica
October 2024
Biolab, PoliToBIOMed Lab, Department of Electronics and Telecommunications, Politecnico di Torino, Turin, Italy.
Objective: Stain normalization is a technique used to standardize the color appearance of digital whole slide images (WSIs). This study aimed to assess the impact of digital stain normalization on prostate cancer diagnosis by pathologists.
Methods: A multi-institutional board of four pathologists evaluated 407 hematoxylin and eosin (H&E) prostate WSIs before and after stain normalization.
Prostate
January 2025
Department of Medical Oncology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
Background: The Nectin-4 directed antibody drug conjugate enfortumab vedotin (EV) has emerged as frontline systemic therapy in combination with immune checkpoint blockade for urothelial carcinoma (UC), capitalizing on the ubiquitous expression of this protein in UC. There is limited data available regarding expression of Nectin-4 by immunohistochemistry in prostate cancer, but this is of interest as a substantial number of UC patients likely to receive EV have concomitant prostate cancer.
Methods: Nectin-4 protein expression was evaluated by immunohistochemistry in tissue microarrays encompassing a cohort of 302 prostatic adenocarcinomas spanning Grade Groups 1-5.
Clin Oncol (R Coll Radiol)
December 2024
Alberta Health Services, South Zone, Lethbridge, AB, Canada; University of Calgary, Department of Oncology, Calgary, AB, Canada; University of Calgary, Department of Physics and Astronomy, Calgary, AB, Canada.
Aims: Prostrate-specific membrane antigen positron emission tomography (PSMA-PET) imaging has led to an increase in identifiable small volume metastatic disease in prostate adenocarcinoma. There is clinical equipoise in how to treat these using radiotherapy regimens. The aim of this study is to determine an adequate dosing regimen for small volume lymphatic metastases in prostate adenocarcinoma.
View Article and Find Full Text PDFInt J Cancer
December 2024
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Survival differences in rare histological prostate cancer (PCa) subtypes relative to age-matched population-based controls are unknown. Within Surveillance, Epidemiology, and End Results database (2004-2020), newly diagnosed (2004-2015) PCa patients were identified. Relying on the Social Security Administration Life Tables (2004-2020) with 5 years of follow-up, age-matched population-based controls (Monte Carlo simulation) were simulated for each patient.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!